Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason S Lewis

Showing results (261-270 of 359) with videos related to

Pageof 36
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2019
Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist <sup>177</sup>Lu-Satoreotide TetraxetanDiane Reidy-Lagunes, Neeta Pandit-Taskar, Joseph A O'Donoghue, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 26, 2014
A modular labeling strategy for in vivo PET and near-infrared fluorescence imaging of nanoparticle tumor targetingCarlos Pérez-Medina, Dalya Abdel-Atti, Yachao Zhang, et al.
Journal of Labelled Compounds & Radiopharmaceuticals|January 26, 2016
Radiosynthesis of the iodine-124 labeled Hsp90 inhibitor PU-H71Tony Taldone, Danuta Zatorska, Stefan O Ochiana, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2019
Retooling a Blood-Based Biomarker: Phase I Assessment of the High-Affinity CA19-9 Antibody HuMab-5B1 for Immuno-PET Imaging of Pancreatic CancerChristian Lohrmann, Eileen M O'Reilly, Joseph A O'Donoghue, et al.
Cancer Discovery|May 12, 2012
Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigenDavid Ulmert, Michael J Evans, Jason P Holland, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2020
Targeted Brain Tumor Radiotherapy Using an Auger EmitterGiacomo Pirovano, Stephen A Jannetti, Lukas M Carter, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 21, 2022
Molecular Imaging of Neuroendocrine Prostate Cancer by Targeting Delta-Like Ligand 3Joshua A Korsen, Teja M Kalidindi, Samantha Khitrov, et al.
Radiology|June 10, 2020
Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted <sup>89</sup>Zr-Pertuzumab PET/CTGary A Ulaner, Jorge A Carrasquillo, Christopher C Riedl, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 14, 2013
Applying PET to broaden the diagnostic utility of the clinically validated CA19.9 serum biomarker for oncologyNerissa Therese Viola-Villegas, Samuel L Rice, Sean Carlin, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 23, 2022
Noninvasive Assessment of Human Epidermal Growth Factor Receptor 2 (HER2) in Esophagogastric Cancer Using <sup>89</sup>Zr-Trastuzumab PET: A Pilot StudyMelissa A Lumish, Steven B Maron, Viktoriya Paroder, et al.
Pageof 36

Showing results (261-270 of 359) with videos related to

Sort By:
Pageof 36
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2019
Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist <sup>177</sup>Lu-Satoreotide TetraxetanDiane Reidy-Lagunes, Neeta Pandit-Taskar, Joseph A O'Donoghue, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 26, 2014
A modular labeling strategy for in vivo PET and near-infrared fluorescence imaging of nanoparticle tumor targetingCarlos Pérez-Medina, Dalya Abdel-Atti, Yachao Zhang, et al.
Journal of Labelled Compounds & Radiopharmaceuticals|January 26, 2016
Radiosynthesis of the iodine-124 labeled Hsp90 inhibitor PU-H71Tony Taldone, Danuta Zatorska, Stefan O Ochiana, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2019
Retooling a Blood-Based Biomarker: Phase I Assessment of the High-Affinity CA19-9 Antibody HuMab-5B1 for Immuno-PET Imaging of Pancreatic CancerChristian Lohrmann, Eileen M O'Reilly, Joseph A O'Donoghue, et al.
Cancer Discovery|May 12, 2012
Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigenDavid Ulmert, Michael J Evans, Jason P Holland, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2020
Targeted Brain Tumor Radiotherapy Using an Auger EmitterGiacomo Pirovano, Stephen A Jannetti, Lukas M Carter, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 21, 2022
Molecular Imaging of Neuroendocrine Prostate Cancer by Targeting Delta-Like Ligand 3Joshua A Korsen, Teja M Kalidindi, Samantha Khitrov, et al.
Radiology|June 10, 2020
Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted <sup>89</sup>Zr-Pertuzumab PET/CTGary A Ulaner, Jorge A Carrasquillo, Christopher C Riedl, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 14, 2013
Applying PET to broaden the diagnostic utility of the clinically validated CA19.9 serum biomarker for oncologyNerissa Therese Viola-Villegas, Samuel L Rice, Sean Carlin, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 23, 2022
Noninvasive Assessment of Human Epidermal Growth Factor Receptor 2 (HER2) in Esophagogastric Cancer Using <sup>89</sup>Zr-Trastuzumab PET: A Pilot StudyMelissa A Lumish, Steven B Maron, Viktoriya Paroder, et al.
Pageof 36